Shulph Ink
Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy
Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy
YOU SAVE £17.32
- Condition: Brand new
- UK Delivery times: Usually arrives within 2 - 3 working days
- UK Shipping: Fee starts at £2.39. Subject to product weight & dimension
Couldn't load pickup availability
Excellent- More about Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy
The book "Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy" discusses targeted drugs that inhibit pathogenic kinases, which have been validated as effective in cancer treatment. Written by experts, it is a valuable resource for cancer researchers and professionals.
Format: Paperback / softback
Length: 502 pages
Publication date: 15 April 2024
Publisher: Elsevier Science & Technology
The field of cancer therapy has seen a significant surge in the development of novel treatments based on molecular targets that are genetically altered in cancer cells. These targets play a crucial role in tumor development and survival, making them ideal targets for therapeutic intervention. Researchers have dedicated substantial efforts to the development of targeted drugs that inhibit the action of pathogenic kinases, which are enzymes responsible for regulating cellular processes.
Clinical studies have validated the positive effects of kinase inhibitors in cancer treatment, providing hope for patients with difficult-to-treat cancers. The book "Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy" serves as a comprehensive resource for cancer researchers, oncologists, graduate students, and members of the biomedical field. It provides detailed discussions on various molecular targets, including ALK2, ATR, CK,Src-Abl, EGFR, Fyn-Blk-Lyn, IGFs, and PAK1.
Each chapter is written by experts who are actively engaged in research on these targets, ensuring that readers gain a deep understanding of their potential applications in cancer therapy. The book offers valuable insights into the mechanisms of action of these targets, their role in tumorigenesis, and the development of targeted drugs that can effectively inhibit their activity.
Furthermore, the book provides practical information on the clinical trials and clinical applications of these molecular targets, including dosage, administration, and potential side effects. It serves as a valuable guide for researchers and clinicians seeking to explore the potential of novel cancer therapies based on molecular targets.
In conclusion, "Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy" is a indispensable resource for anyone interested in the field of cancer therapy. It provides a comprehensive overview of the latest developments in this area, highlighting the importance of molecular targets in cancer treatment and the potential for targeted drugs to revolutionize the way we approach cancer care.
Weight: 1040g
Dimension: 232 x 190 x 29 (mm)
ISBN-13: 9780323961219
This item can be found in:
UK and International shipping information
UK and International shipping information
UK Delivery and returns information:
- Delivery within 2 - 3 days when ordering in the UK.
- Shipping fee for UK customers from £2.39. Fully tracked shipping service available.
- Returns policy: Return within 30 days of receipt for full refund.
International deliveries:
Shulph Ink now ships to Australia, Belgium, Canada, France, Germany, Ireland, Italy, India, Luxembourg Saudi Arabia, Singapore, Spain, Netherlands, New Zealand, United Arab Emirates, United States of America.
- Delivery times: within 5 - 10 days for international orders.
- Shipping fee: charges vary for overseas orders. Only tracked services are available for most international orders. Some countries have untracked shipping options.
- Customs charges: If ordering to addresses outside the United Kingdom, you may or may not incur additional customs and duties fees during local delivery.
